Table 5.

Multivariable odds ratios (OR) and 95% confidence intervals (CI) for associations between patient characteristics, treatment regimen (dichotomized as monotherapy/combination therapy)†, and risk of emergent renal dysfunction (top) or hepatic dysfunction (bottom)

Characteristic or treatment regimen	Total	Events, n (% total)	Adjusted OR a (95% CI)	p value
Emergent renal dysfunction (82 events/1,778 total)
Age
<70 yr	935	36 (3.9)	Ref
70+ yr	843	46 (5.5)	1.67(1.03–2.70)	.039
Sex
Female	569	16 (2.8)	Ref
Male	1,209	66 (5.5)	1.92(1.17–3.14)	.012
State at diagnosis
III/IV	930	41 (4.4)	Ref
0/I/II	486	25 (5.1)	1.14(0.74–1.76)	.541
Unknown	362	16 (4.4)	1.00(0.65–1.54)	.996
Practice type
Academic practice	292	14 (4.8)	Ref
Community	1,486	68 (4.6)	0.85(0.33–2.21)	.746
Treatment regimen b
Monotherapy	1,402	53 (3.8)	Ref
Combination therapy	376	29 (7.7)	2.47(1.48–4.12)	<.001
Emergent hepatic dysfunction (119 events/1,616 total)
Age
<70 yr	831	79 (9.5)	Ref
70+ yr	785	40 (5.1)	0.60(0.39– 0.93)	.023
Sex
Female	503	39 (7.8)	Ref
Male	1,113	80 (7.2)	0.96(0.66– 1.40)	.821
Stage at diagnosis
III/IV	836	68 (8.1)	Ref
0/I/II	435	32 (7.4)	0.96(0.63– 1.45)	.836
Unknown	345	19 (5.5)	0.69(0.42– 1.13)	.145
Practice type
Academic practice	165	10 (6.1)	Ref
Community	1,451	109 (7.5)	1.23(0.66– 2.29)	.506
Treatment regimen b
Monotherapy	1,288	75 (5.8)	Ref
Combination therapy	328	44 (13.4)	2.17(1.46–3.23)	<.001

^aModels adjusted for all variables listed.

^bNote: Patients may have received second‐line ICI or other relevant treatment subsequent to treatment start and prior to identification of emergent dysfunction.

Ref, reference.